Redhill Biopharma Ltd (NASDAQ:RDHL)

7.90
Delayed Data
As of Jun 22
 +0.06 / +0.77%
Today’s Change
4.30
Today|||52-Week Range
11.25
+53.70%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$146.8M

Company Description

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA  (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA  (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA  (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases. The company also commercializes and promotes gastrointestinal products in the United States. RedHill Biopharma was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:

Employees

Shareholders

Other institutional16.90%
Mutual fund holders1.23%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Gilead RadayChief Operating Officer
Micha Ben-ChorinChief Financial Officer
Reza FathiSenior Vice President-Research & Development
David WassermanVP-Business Alliance & Compliance Officer